Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.53 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21715595 | 0.91 | OTUD7B (0.50) | OTUD7BPYGBNEK2CDK8CDK19 | |
| SCHEMBL606993 | 0.87 | NEK2 (0.48) | OTUD7BPYGBNEK2CDK8CDK19 | |
| Hydrochloric Acid SCHEMBL5612051 | 0.85 | NEK2 (0.47) | OTUD7BPYGBNEK2CDK8CDK19 | |
| SCHEMBL14377163 | 0.83 | OTUD7B (0.45) | OTUD7BPYGBCDK8CDK19 | |
| SCHEMBL14377201 | 0.82 | OTUD7B (0.55) | OTUD7BPYGBNEK2CDK8CDK19 | |
| SCHEMBL15001635 | 0.81 | OTUD7B (0.46) | OTUD7BPYGBNEK2 | |
| SCHEMBL31421433 | 0.78 | OTUD7B (0.51) | OTUD7BPYGBNEK2CDK8CDK19 | |
| SCHEMBL2490406 | 0.72 | CRBN (0.32) | — | |
| SCHEMBL20608003 | 0.71 | OTUD7B (1.00) | OTUD7B | |
| SCHEMBL21778139 | 0.71 | OTUD7B (0.51) | OTUD7BPYGBCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250115612-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AND OCTAHYDROFURO[3,4-B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2025-04-10 | — | — | US | disclosed |
| WO-2025011494-A1 | CRYSTAL FORM OF PIPERAZINO RING-CONTAINING DERIVATIVE, SALT FORM, PREPARATION METHOD, AND USE | 优领医药科技(香港)有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-20240417393-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | US | disclosed |
| EP-4464704-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Acerand Therapeutics (Hong Kong) Limited (HK) | 2024-11-20 | — | — | EP | disclosed |
| EP-4412707-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2024-08-14 | — | — | EP | disclosed |
| CN-112778183-B | Nitrogen-containing ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116425744-A | Piperazine-containing ring derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0357047-A1 | Spiro compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | OTUD7B 4605/4885PYGB 3036/4885NEK2 2705/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | OTUD7B 2188/4885PYGB 3958/4885NEK2 3202/4885 |
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PARP1, PARP11, PARP15 | OTUD7B 2970/4885PYGB 348/4885NEK2 499/4885 |
| US-20250115612-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AND OCTAHYDROFURO[3,4-B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | OTUD7B 4198/4885PYGB 2077/4885NEK2 3714/4885 |
| US-20240417393-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | OTUD7B 4209/4885PYGB 2129/4885NEK2 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.